Logo Inventiva Pharma
  • About Inventiva
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Our people
  • Therapeutic Areas
    • Non-alcoholic steatohepatitis (NASH)
    • Mucopolysaccharidosis (MPS)
    • Publications
    • PanNASH Initiative
  • Pipeline
    • Lanifibranor
    • Odiparcil
    • YAP-TEAD
    • Clinical Trials
    • Our Partners
    • Inventiva Expanded Access Policy
  • Investors
    • Corporate Governance
      • Leadership
      • Board of Directors
      • Committee Composition
    • Financial Calendar
    • Results & Presentations
    • Investor Presentations
    • Regulated Information
    • Shareholder Meetings
    • Stock Market Data
      • Stock Quote – Euronext Paris
      • Stock Chart – Euronext Paris
      • Stock Quote – NASDAQ
      • Historic Price Lookup
      • Investment Calculator
    • SEC Filings
    • Share Information
    • Analyst Coverage
    • Investor Resources
      • IR Contacts
  • News & Events
  • Contact Us
  • Fr
  • En
News & Events
Home - News & Events
Email Alerts

Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvement

25 February 2021

Inventiva to participate at several investor conferences in March 2021

24 February 2021

Inventiva’s 2020 Full-Year Financial Results Presentation

23 February 2021

Full-Year 2020: Cash position and revenues

11 February 2021

Inventiva to present at the 39th Annual J.P. Morgan Healthcare Conference

6 January 2021

Inventiva announces design of Phase III clinical trial with lanifibranor in NASH

5 January 2021

Inventiva announces the publication in the Journal of Hepatology of new pre-clinical data showing the beneficial effects of lanifibranor on cirrhosis

7 December 2020

Inventiva to participate at the Piper Sandler 32nd Annual Virtual Healthcare Conference

24 November 2020

Q3 2020 Financial Information

12 November 2020
Load More

Upcoming Investors Meetings


Upcoming Science Conferences


Questions?
Get in touch!


Inventiva
Frédéric Cren

Chief Executive Officer
info@inventivapharma.com
+33 3 80 44 75 00

Brunswick
Yannick Tetzlaff / Tristan Roquet Montegon / Aude Lepreux

Media relations
inventiva@brunswickgroup.com
+33 1 53 96 83 83

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com

About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical need in the areas of fibrosis, lysosomal storage disorders and oncology.

Jump to

  • Legal information
  • Contact Us
  • Home
  • Legal information
  • Contact Us

© 2021 Inventiva. All rights reserved. Privacy Policy – Legal Information

News & Events